New drug combinations for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have breast cancer that has spread to other parts of the body (metastatic) or is locally advanced and cannot be removed by surgery.
- Your cancer is ER-positive, HER2-positive or HER2-negative, or triple-negative breast cancer.
- Your cancer has gotten worse (progressed) during or after your last treatment.
- You have at least one tumor that can be measured on a scan (like a CT scan) that is not in the brain.
- You are in good enough health to participate, with no active infections, serious heart or lung problems, or other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This study tests a new drug (SHR-1811) combined with a standard chemotherapy drug (carboplatin) for advanced breast cancer that shows HER2, even at low levels. It may offer a new option for people whose cancer has stopped responding to previous treatments.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests a new drug (SHR2554) combined with standard hormone therapy for people with advanced or metastatic breast cancer. The goal is to see if the combination helps control the cancer better.
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.